---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024479"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:09:58.669893+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q3 net loss $11.4M; cash $90.4M; enrollment milestones updated

## Summary
- Cash, cash equivalents and investments totaled $90.4M as of Sept 30, 2022.
- Net loss for Q3 2022 was $11.4M, flat YoY; R&D expenses $8.8M vs $8.6M.
- CAHmelia-203 approaching 50% enrollment; CAHmelia-204 surpassed 25% enrollment.
- Appointed Saba Sile, M.D., as VP of Clinical Development from Horizon Therapeutics.
- Topline results expected: PCOS trial H1 2023; CAHmelia-203 H2 2023; CAHmelia-204 H2 2024.

## SEC filing metadata
- accession: 0000950170-22-024479
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/0000950170-22-024479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/sprb-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024479
- JSON: https://secwatch.observer/filing/0000950170-22-024479.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024479.txt

## Key facts
- Earnings Releases
  SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $11.4 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $11.4 million
  - Result: reported results
  source text: Net loss for the three and nine months ended September 30, 2022 was $11.4 million and $35.0 million, respectively, compared to $11.4 million and $33.1 million, respectively, for the same periods in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/0000950170-22-024479-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.